Dova Pharmaceuticals Inc (NASDAQ:DOVA) has earned an average recommendation of “Hold” from the eight brokerages that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and three have given a buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $36.00.

DOVA has been the subject of several research reports. Jefferies Financial Group reiterated a “buy” rating and issued a $40.00 target price on shares of Dova Pharmaceuticals in a research report on Sunday, July 15th. Zacks Investment Research lowered shares of Dova Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, July 16th. BidaskClub lowered shares of Dova Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 2nd. Raymond James initiated coverage on shares of Dova Pharmaceuticals in a research report on Wednesday, August 29th. They issued an “outperform” rating and a $44.00 target price for the company. Finally, Leerink Swann cut their target price on shares of Dova Pharmaceuticals from $32.00 to $31.00 and set a “market perform” rating for the company in a research report on Tuesday, September 4th.

In related news, CEO Alex Sapir bought 21,700 shares of the business’s stock in a transaction that occurred on Tuesday, August 14th. The stock was bought at an average cost of $22.83 per share, for a total transaction of $495,411.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 55.50% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of America Corp DE boosted its position in Dova Pharmaceuticals by 81.3% during the second quarter. Bank of America Corp DE now owns 5,305 shares of the company’s stock valued at $159,000 after buying an additional 2,379 shares during the period. JPMorgan Chase & Co. boosted its position in Dova Pharmaceuticals by 148.6% during the first quarter. JPMorgan Chase & Co. now owns 5,345 shares of the company’s stock valued at $145,000 after buying an additional 3,195 shares during the period. Schwab Charles Investment Management Inc. boosted its position in Dova Pharmaceuticals by 36.4% during the first quarter. Schwab Charles Investment Management Inc. now owns 13,500 shares of the company’s stock valued at $367,000 after buying an additional 3,600 shares during the period. Metropolitan Life Insurance Co. NY purchased a new stake in Dova Pharmaceuticals during the second quarter valued at about $128,000. Finally, MetLife Investment Advisors LLC purchased a new stake in Dova Pharmaceuticals during the second quarter valued at about $181,000. Institutional investors and hedge funds own 36.64% of the company’s stock.

Shares of Dova Pharmaceuticals stock traded down $2.41 during trading on Friday, hitting $16.89. The stock had a trading volume of 647,924 shares, compared to its average volume of 144,409. The stock has a market cap of $527.66 million, a P/E ratio of -12.06 and a beta of 0.87. Dova Pharmaceuticals has a 12 month low of $16.63 and a 12 month high of $37.00. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.14 and a current ratio of 13.19.

Dova Pharmaceuticals (NASDAQ:DOVA) last released its quarterly earnings results on Thursday, November 8th. The company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.12. The firm had revenue of $2.93 million during the quarter, compared to the consensus estimate of $2.66 million. Sell-side analysts predict that Dova Pharmaceuticals will post -2.76 earnings per share for the current year.

Dova Pharmaceuticals Company Profile

Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.

Read More: Index Funds

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.